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A new strain, namely Lysinibacillus sp. BV152.1 was isolated from the rhizosphere of
ground ivy (Glechoma hederacea L.) producing metabolites with potent ability to inhibit
biofilm formation of an important human pathogens Pseudomonas aeruginosa PAO1,
Staphylococcus aureus, and Serratia marcescens. Structural characterization revealed
di-rhamnolipids mixture containing rhamnose (Rha)-Rha-C10-C10, Rha-Rha-C8-C10,
and Rha-Rha-C10-C12 in the ratio 7:2:1 as the active principle. Purified di-rhamnolipids,
as well as commercially available di-rhamnolipids (Rha-Rha-C10-C10, 93%) were used
as the substrate for the chemical derivatization for the first time, yielding three semi-
synthetic amide derivatives, benzyl-, piperidine-, and morpholine. A comparative study
of the anti-biofilm, antibacterial and cytotoxic properties revealed that di-Rha from
Lysinibacillus sp. BV152.1 were more potent in biofilm inhibition, both cell adhesion
and biofilm maturation, than commercial di-rhamnolipids inhibiting 50% of P. aeruginosa
PAO1 biofilm formation at 50 µg mL−1 and 75 µg mL−1, respectively. None of the di-
rhamnolipids exhibited antimicrobial properties at concentrations of up to 500 µg mL−1.
Amide derivatization improved inhibition of biofilm formation and dispersion activities of
di-rhamnolipids from both sources, with morpholine derivative being the most active
causing more than 80% biofilm inhibition at concentrations 100 µg mL−1. Semi-
synthetic amide derivatives showed increased antibacterial activity against S. aureus,
and also showed higher cytotoxicity. Therefore, described di-rhamnolipids are potent
anti-biofilm agents and the described approach can be seen as viable approach in
reaching new rhamnolipid based derivatives with tailored biological properties.
Keywords: rhamnolipids, di-rhamnolipids, biofilms, cell adhesion, amide derivative
INTRODUCTION
Microbial biofilms are prevalent in nature, especially in medical, industrial and environmental
settings where they cause undesirable effects due to their pathogenicity and resistance toward
antibiotics or biofouling technologies (Berlanga and Guerrero, 2016; Holscher and Kovacs, 2017).
Biofilms play an important role in virulence of many pathogenic bacteria including Pseudomonas
aeruginosa, Staphylococcus aureus, and Serratia marcescens (Costerton et al., 1999; Singh et al.,
2000; Bryers, 2008). They can be formed in the patients’ tissues or on the surface of medical
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devices associated with the human body such as catheters, naso-
laryngeal tubes, or stents (Bryers, 2008). Various strategies have
been developed and employed for the efficient biofilm control
(Coughlan et al., 2016; Rowson and Townsend, 2016), however,
new, natural, and effective anti-biofilm agents are still highly
sought after. Application of microbial biosurfactants in anti-
biofilm and antibiofouling efforts emerged as an attractive and
one of the viable strategies in recent years (Vatsa et al., 2010;
Varjani and Upasani, 2017).
Biotechnological interest in biosurfactants has grown
exponentially since the 1980s when these molecules were found
useful in oil recovery and bioremediation (Abdel-Mawgoud
et al., 2010; Muller et al., 2012; Dobler et al., 2016). Rhamnolipids
as a group of anionic microbial glycolipids, consisting of
L-(+)-rhamnose and β-hydroxyalkanoic acids, have been
considered in a wide range of applications such as health
care, cosmetics, pharmaceutical processes, food and beverage
processing, detergents and polymer industry, cryo-protectants,
biofuels, microbial fuel cells, and bioremediation, due to their
unique characteristics such as low toxicity, surface activities,
sustainability, and biodegradability (Li, 2017; Varjani and
Upasani, 2017).
Rhamnolipids were firstly described as secondary metabolites
of P. aeruginosa in 1949 and were found essential for the
growth of this bacterium on hydrophobic carbon sources (Muller
et al., 2011; Gong et al., 2015), but are also critical for forming
structured biofilms with pore and channels in this organism
(Davey et al., 2003). So far, over 60 rhamnolipid congeners
and homologs have been described, including mono- and
di-rhamnolipids, containing mostly two, one, or even three
molecules of β-hydroxyalkanoic acids with varying carbon chain
length (Abdel-Mawgoud et al., 2010). Rhamnolipids reached
the market as an active ingredient of Zonix TM fungicide
(Jeneil Biosurfactants Co., Saukville, WI, United States), and
there is a number of reports regarding their antibacterial
and anti-biofilm activities (Abdel-Mawgoud et al., 2010; Vatsa
et al., 2010; Kim et al., 2015; Zhong et al., 2015). Di-
rhamnolipids (di-Rha), as a class of rhamnolipids, are less
studied but received attention as they showed therapeutic
properties for wound healing and ulcer treatment (Stipcevic
et al., 2006; Piljac et al., 2008). Stable rhamnolipid production
has been achieved with P. aeruginosa and certain Burkholderia
strains (Chrzanowski et al., 2012; Dobler et al., 2016),
however, the identification and the development of other
rhamnolipid producing bacteria is an important issue to avoid
potential pathogenicity and to broaden the spectrum of the
products.
In this study, we sought to identify secondary
metabolites amongst metabolites of new bacterial isolates
that would have efficient anti-biofilm activity preferably
without the effect on bacterial growth, to avoid the
development of resistance. As the most activity has been
associated with the di-rhamnolipids, the investigation
has been extended to the semi-synthetic preparation of
di-rhamnolipids amide derivatives and comprehensive
assessment of their anti-biofilm, antibacterial, and cytotoxic
activities.
MATERIALS AND METHODS
Materials
Chemicals and reagents including rhamnolipids mixture
R90 (AGAE Technologies) and 4-(Dimethylamino)pyridine
(DMAP) were purchased from Sigma–Aldrich (Munich,
Germany). Reagents used for coupling reactions including N-
(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride
(EDCI) were purchased from ACROS Organics (Morris
Plains, NJ, United States). Unless otherwise stated, all
media components were purchased either from Oxoid
(Cambridge, United Kingdom) or Becton Dickinson (Sparks,
MD, United States).
Gentamycin sulfate and chloramphenicol were purchased
from Sigma–Aldrich (Munich, Germany), tetracycline
hydrochloride from USB Co. (Cleveland, OH, United States) and
cycloheximide from SERVA (Heidelberg, Germany). The stock
solutions of antibiotics were prepared as follows: gentamycin 30 g
L−1 in water, tetracycline 15 g L−1 in ethanol, chloramphenicol
50 g L−1 in ethanol, and cycloheximide 70 g L−1 in water and
were kept at−20◦C.
Isolation and Identification of Bacterium
BV152.1
Bacteria were isolated from the rhizosphere of medicinal plant
Glechoma hederacea L. (ground ivy), using previously described
procedure (Djokic et al., 2011). The medium for isolation
of bacteria was starch casein agar containing soluble starch
(10 g L−1), casein (1 g L−1), KH2PO4 (0.5 g L−1), MgSO4
(0.5 g L−1), NaCl (3 g L−1), and bacteriological agar (15 g L−1),
supplemented with antifungal cycloheximide (50 µg L−1). Plates
were incubated at 30◦C for 7 days.
Isolates were grown in JS broth containing soy flour
(30 g L−1), soluble starch (20 g L−1), glucose (20 g L−1), mannitol
(15 g L−1), and CaCO3 (10 g L−1) for 7 days, at 30◦C on a rotary
shaker (180 rpm) and their cultures were extracted with equal
volume of ethyl acetate and screened for the inhibition of biofilm
formation of P. aeruginosa PAO1.
Genomic DNA isolation, PCR amplification of 16S rRNA gene
sequencing and sequence alignment were performed as described
previously (Stankovic et al., 2012).
Preparation and Analysis of BV152.1
Culture Extracts
Spore suspensions of BV152.1 were prepared in glycerol [20%,
v/v, (Kieser et al., 2000)] (20 µl) and firstly inoculated into
vegetative medium (tryptone soy broth, 8 g L−1, yeast extract,
4 g L−1, maltose, 15 g L−1, and CaCO3, 2 g L−1) and incubated
at 30◦C for 48 h, and this pre-culture was then used for the
inoculation of JS broth (1%, v/v). Cultures were grown in
Erlenmeyer flasks (1:5 culture to volume ratio) containing coiled
stainless steel spring for better aeration and incubated at 30◦C on
a rotary shaker (180 rpm) for 7 days.
Culture (1 L) was extracted using the equal volume of ethyl
acetate by vigorous shaking for 30 min. The organic phase was
then separated, dried under vacuum and further purified by flash
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chromatography. Flash chromatography employed silica gel 60
(230–400 mesh) and the following solvent system: n-hexane and
ethyl acetate (3:1 ratio, 100 ml), n-hexane and ethyl acetate (1:1
ratio, 100 ml), ethyl acetate and methanol (9:1 ratio, 100 ml),
followed by pure methanol (100 ml). Collected fractions were
analyzed by thin layer chromatography, which was carried out
using alumina plates with 0.25 mm silica layer (Kieselgel 60
F254, Merck, Darmstadt, Germany) and the appropriate fractions
were combined, dried under vacuum, and weighted. Anti-biofilm
activity was determined for each fraction.
Purification and Characterization of
Di-Rhamnolipids
The fraction that showed anti-biofilm forming activity was
purified further using the following solvents: pure ethyl acetate
(50 mL); ethyl acetate, dichloromethane, and methanol (8:1:1
ratio, 50 mL) and ethyl acetate, dichloromethane, and methanol
(4:2:1 ratio, 50 mL). The most active fraction (F3) was further
analyzed by a combination of NMR and mass spectrometry. The
NMR spectra were recorded on a Bruker Ascend 400 (400 MHz)
spectrometer. Chemical shifts are given in parts per million (δ)
downfield from tetramethylsilane as the internal standard and
deuterochloroform as a solvent.
Mass spectral data were recorded using 6210 Time-of-
Flight LC–MS system (Agilent Technologies, Santa Clara, CA,
United States) connected to an Agilent 1200 Series HPLC
instrument (Agilent Technologies, Waldbronn, Germany), with a
degasser, a binary pump, an autosampler, a column compartment
equipped with a Zorbax Eclipse XDB-C18 RRHT column
(1.8 µm, 4.6 mm × 50 mm) and a diode-array detector, via ESI
interface. The mobile phase consisted of water containing 0.2%
formic acid (v/v; A) and acetonitrile (B). A gradient program
was used as follows: 0–0.24 min 5% B, 0.24–10 min, 5–95% B,
10–15 min, 95% B, 15–15.5 min, 95–5% B, 15.5–20 min, 5%
B. The flow rate of mobile phase was 0.5 mL/min, the column
temperature was 40◦C and the injection volume was 10 µL.
Spectral data from all the peaks were accumulated in the range
of 190–900 nm. Full scan mass spectra were measured between
100 and 1500 m/z in positive ion mode.
Synthesis and Characterization of
Bacterial Rhamnolipid Derivatives
To a solution of di-rhamnolipids (0.1 mmol, 1 eq.) in
CH2Cl2/DMF (2.7:0.3 mL) were added EDCI (0.12 mmol, 1.2
eq.), DMAP (0.05 mmol, 0.5 eq.) and amine (benzyl amine,
piperidine and morpholine; 0.3 mmol, 3 eq.). The mixture was
stirred for 16 h at room temperature. The mixture was diluted
with water (10 mL) and extracted with CH2Cl2 (3 × 15 mL).
The combined organic extract was dried with MgSO4, filtered and
concentrated in vacuo. The residue was purified by flash column
chromatography (SiO2, ethyl acetate:methanol:dichloromethane
in 4:2:1 ratio) that afforded products as yellow thick oils.
To obtain silylated derivative to a solution of rhamnolipids
(0.1 mmol, 1 eq.) in DMF (3 mL) TBDMS-Cl (1.6 mmol, 16 eq.)
AgNO3 (1.6 mmol, 16 eq.) and pyridine (3.2 mmol, 32 eq.) were
added. The mixture was stirred overnight at ambient temperature
before it was diluted with water (10 mL) and extracted with ethyl
acetate (3 × 20 mL). The combined organic extract was dried
with MgSO4, filtered and concentrated in vacuum to yield the
product which was purified via silica gel flash chromatography
using petroleum ether/EtOAc (7:1) as eluent to provide the title
compound as a colorless oil.
Physico-chemical properties of all compounds were predicted
using the Marvin Sketch 17.2.13.0 program (ChemAxon1).
Consensus methods were used for calculating logP and
hydrophilic-lipophilic balance (HLB) values.
Test Organisms
Test organisms for the antibacterial assays were obtained from
the National Collection of Type Cultures (NCTC) and the
American Type Culture Collection (ATCC). P. aeruginosa PAO1
NCTC 10332, S. aureus ATCC 25923 and S. aureus ATCC 43300
(MRSA) and S. marcescens ATCC 27117 were used in this study.
One clinical isolate of P. aeruginosa DM50 with high ability to
form biofilms and resistance to metronidazole, clindamycin and
amoxicillin was also included (Glisic et al., 2016). Bacterial strains
were grown in Luria Bertani (LB) broth at 37◦C on a rotary shaker
at 180 rpm.
All rhamnolipids utilized for the bioactivity assessments in
this study along with sources and descriptions are listed in
Supplementary Table S1.
Antimicrobial Susceptibility Tests for
Planktonic Cells
The minimum inhibitory concentration (MIC) of rhamnolipids
and their derivatives were determined according to standard
broth microdilution assays recommended by the National
Committee for Clinical Laboratory Standards (M07-A8).
Stock solutions of rhamnolipids and derivatives were prepared
in DMSO (50 g L−1, w/v). The highest concentration used was
500 mg L−1. The inoculums were 105 colony forming units (cfu)
mL−1. The MIC value corresponds to the lowest concentration
that inhibited the growth after 24 h at 37◦C for P. aeruginosa and
S. aureus or at 30◦C for S. marcescens.
Inhibition of Biofilm Formation
Biofilm quantification assays were performed in 96-well
microtiter plates using a crystal violet (CV) method to stain
adherent cells (Merritt et al., 2005). Overnight cultures of bacteria
were diluted to 5× 107 cfu mL−1 in LB and 100 µL was added to
the wells in the presence of test compounds or DMSO (0.1%, v/v).
Biofilms formed for 24 h at 37◦C for P. aeruginosa and S. aureus,
or 30◦C for S. marcescens were washed and adherent cells stained
with CV 0.1% (v/v). BFIC50 (concentration of compound that
inhibited biofilm formation by 50%) was determined for each
compound.
The effect of rhamnolipids on P. aeruginosa biofilm formation
was examined additionally by introducing 3 h adhesion phase
after inoculation with 5 × 107 cfu mL−1 cells. Following
adhesion, the supernatant was removed and, after two washing
1http://www.chemaxon.com
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steps with phosphate buffered saline (PBS), test compounds or
DMSO were applied and the biofilms were quantified after 24 h
using CV. Each biofilm formation assay was performed in six
wells and repeated at least three times.
Scanning Electron Microscopy (SEM)
To study the effect of di-rhamnolipids on P. aeruginosa PAO1
adherence to silicone surfaces and overnight bacterial culture was
diluted to 5 × 107 cfu mL−1 in LB and 2 ml was added per well
in six well microtiter plate. The silicone catheter pieces (Romed,
Wilnis, Holland) of 1 cm were placed in each well containing
diluted bacteria and incubated in the presence of di-rhamnolipids
from Lysinibacillus sp. BV152.1 (F3) or DMSO. After 24 h, the
culture medium was removed and the catheters were washed
three times in PBS in order to remove the non-adherent strains.
Biofilms were then fixed with cold methanol and the samples
dried before the examination.
Catheters were glued to double-sided conductive carbon
tab stuck on standard vacuum-clean stub, and were coated
with gold (thickness of 15–20 nm) by the sputtering process
(Leica EM SCD005 sputtering machine, Leica Microsystems,
Mannheim, Germany). Sputtering was performed in the vacuum
chamber under pressure <0.05 mbar using sputter current of
40 mA, the working distance of 50 mm and sputter time of
100 s. Such prepared samples were examined by JEOL JSM-
6610LV microscope (JEOL United States, Inc., Peabody, MA,
United States). An acceleration voltage of 20 kV was used.
Biofilm Microscopy
To study the effect of di-rhamnolipids on P. aeruginosa PAO1
adherence to glass or plastic surfaces biofilms were developed on
cover slips and examined under the microscope. An overnight
culture of P. aeruginosa PAO1 was diluted to 5 × 107 cfu mL−1
in LB and 2 ml was added per well of six well microtiter plate
containing glass or plastic cover slips. After 24 h, non-adherent
cells were removed and biofilms were washed with 0.9% NaCl
and stained with 2.5 µM SYTO9 green fluorescent dye and
2.5 µM propidium iodide (PI) red fluorescent dye of Live/Dead
staining kit (LIVE/DEAD R© BacLightTM Bacterial Viability Kit,
Thermo Fisher Scientific, Waltham, MA, United States). Cells
were observed under a fluorescence microscope (Olympus BX51,
Applied Imaging Corp., San Jose, CA, United States) under
100,000 × magnification (glass) or 40,000 × magnification
(plastic).
Anti-adhesion Assay
Anti-adhesion assay was performed as previously described
(Shetye et al., 2014) with some modifications. An overnight
culture of P. aeruginosa PAO1 containing pBBR2-GFP (da Silva
et al., 2014) was subcultured (initial OD600 = 0.02) in M9+/LB
(95:5) containing gentamycin (80 mg L−1), tetracycline (20 mg
L−1), and chloramphenicol (50 mg L−1) at 37◦C in a rotary
shaker (200 rpm). After reaching OD600= 0.1, aliquots (200 µL)
were transferred to the wells of black polystyrene microtiter
plate with rhamnolipids, derivatives or DMSO (control). After
incubation at 37◦C for 2 h, bacterial cultures were discarded, and
the fluorescence of adherent cells was measured after addition
of fresh M9+/LB (95:5) medium using Tecan Infinite 200
Microplate reader (Tecan Group Ltd., Switzerland, lex= 500 nm,
lem = 540 nm). Background signal (M9+/LB (95:5) was
subtracted from all the samples. Assays were repeated three times;
inhibition values are the averages of six replicate wells from one
experiment.
Biofilm Dispersion Assay
An overnight culture of P. aeruginosa was diluted to 5 × 107
cfu mL−1 in LB and 100 µL was added to the wells in 96-well
microtiter plates and incubated for 24 h at 37◦C. After removal of
the supernatant and two washing steps with PBS adherent cells
were treated with different concentrations of rhamnolipids or
derivatives for additional 24 h and the biofilms were quantified
using CV as described above. Biofilm dispersion assays were
performed in six wells and repeated three times.
Cytotoxicity Assay
MRC5 human lung fibroblasts were obtained from the ATCC.
Cells were maintained as monolayer cultures in RPMI-1640
supplemented with 100 mg L−1 streptomycin, 100 U mL−1
penicillin and 10% (v/v) FBS (all from Sigma, Munich, Germany).
Cells were grown in a humidified atmosphere of 95% air and 5%
CO2 at 37◦C.
Cytotoxicity on MRC5 cells was evaluated with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
The assay was carried out after 48 h of cell incubation in the media
containing test compounds at different concentrations and the
viability was measured as described (Mihajlovic et al., 2012). The
results are presented as the percentage of the control (untreated
cells) that was arbitrarily set to 100%.
Statistical Analysis
The results were analyzed by Student’s t-test using SPSS version
20 software. A P-value lower than 0.05 was considered as
statistically significant.
RESULTS
Isolation and Identification of BV152.1
The rhizosphere of medicinal plant G. hederacea L. (ground
ivy) proved a prolific source of aerobic bacteria with 32
morphologically differing isolates collected from this source (data
not shown). Culture extracts from these isolates were screened
for their ability to inhibit biofilm formation in P. aeruginosa
PAO1 using CV based assay in 96-well polystyrene plates. During
the preliminary screening, the crude cell extract of the isolate
BV152.1 showed the most potent ability to inhibit 60% of
biofilm formation when applied in the concentration of 500 µg
mL−1 while no bactericidal activity of the extract was observed.
This isolate was selected for structural characterization of its
secondary metabolites as the most promising one. The isolate
BV152.1 was identified as a member of the Gram-positive genus
Lysinibacillus on the basis of 16S rRNA gene sequence analysis.
Its 16S rRNA gene sequence (GenBank access No. KY933395)
showed 99% similarity with type strains of Lysinibacillus louembei
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NM73 (NR_145586.1), L. meyeri WS 4626 (NR_117577.1), and
L. odysseyi YH2 (KM873372.1).
Di-Rhamnolipids As Active Components
of Lysinibacillus sp. BV152.1 Culture
Extracts
In order to identify the component with biofilm formation
inhibitory activity produced by Lysinibacillus sp. BV152.1, 1 L
culture grown for 7 days at 30◦C was extracted with ethyl acetate
and the total mass of 800 mg crude cell extract was obtained. The
crude cell extract was subsequently fractionated, the activity of
each fraction measured and the fraction designated as F3 was
identified as the most active one. After further purification, the
total mass of F3 was determined to be 60 mg and it showed 50%
inhibition of biofilm formation when applied in a concentration
of 50 µg mL−1 (Table 1).
1H-NMR and 13C-NMR spectra of F3 showed the presence
of fatty acid chains and carbohydrate moieties (Figure 1A)
indicative of the characteristic spectra of bacterial di-
rhamnolipids. The peak observed at δ 0.88 ppm indicated
the presence of terminal methyl group and the peak at δ 1.26,
characteristic for methylene group, indicated the presence of a
straight-chain fatty acid. The peaks observed at δ 4.15–3.36 and
peaks for two anomeric protons at δ 4.90 confirmed the presence
of two carbohydrate units. The 13C-NMR analysis demonstrated
two carbonyl peaks at δ 173.7 and 171.4, two anomeric carbon
peaks at δ 102.5 and 94.5 and expected number of peaks for
carbohydrate and fatty acid units. In general, the spectral
characteristics obtained for F3 (provided in Supplementary
material) were in good agreement with the data published in the
literature for di-rhamnolipids (Sharma et al., 2007).
The exact lengths of the fatty acid chains were deduced
from HPLC-MS data (Figure 1B). Sodiated molecular ions,
[M + Na]+, in the ESI+MS data were observed at m/z 701
(Rha-Rha-C10-C12, 11.16 min, 9%), 699 (Rha-Rha-C10-C12:1,
10.68 min, 8%), 673 (Rha-Rha-C10-C10, 10.03 min, 63%, major),
and 645 (Rha-Rha-C8-C10, 8.96 min, 17%), 527 (Rha-C10-C10,
10.86 min, 3%).
Considering the identified structural characteristics of F3, we
have selected commercially available P. aeruginosa sp. derived
rhamnolipids (R90), as the model and the control compound.
R90 was determined to contain mono- vs. di-rhamnolipid form
in 4:1 ratio (AGAE Technologies, Figure 1C) with the major
component of Rha-Rha-C10-C10 in more than 90%.
Anti-biofilm Properties of
Di-Rhamnolipids
Di-rhamnolipids from Lysinibacillus sp. BV152.1 (F3) containing
mainly di-rhamnolipids with Rha-Rha-C10-C10 63% showed
dose-dependent anti-biofilm formation activity in P. aeruginosa
PAO1 with 50 µg mL−1 determined as BFIC50 (Figure 2A). In
order to assess whether di-rhamnolipids from Lysinibacillus sp.
BV152.1 affected biofilm growth, P. aeruginosa PAO1 cells were
left to attach to the surface of microtiter wells for 2 h prior to
incubation with F3 for 24 h. Inhibition of biofilm formation was
similar in the presence or absence of the cell adhesion phase
showing that di-rhamnolipids affected both cell attachment and
biofilm growth (Figure 2A).
Anti-biofilm properties of di-rhamnolipids from Lysinibacillus
sp. BV152 were compared to that of commercially available
rhamnolipids obtained by fermentation of P. aeruginosa sp. (R90)
(Figure 2B). Di-rhamnolipids (di-Rha) from this sample were
also purified and used for the comparison. Rhamnolipids mixture
(R90) and purified di-Rha from P. aeruginosa showed slightly
lower activity against P. aeruginosa PAO1 biofilm formation
(BFIC50 = 75 µg mL−1) comparing to F3. The effects of R90
and di-Rha on biofilm formation were comparable when the
treatments were applied without cell adhesion phase. However,
when bacteria were left to attach to the surface prior to
treatments, di-Rha stimulated biofilm formation when added
in concentrations up to 50 µg mL−1. Di-rhamnolipids from
TABLE 1 | Antibacterial activity of rhamnolipids mixture (R90), di-rhamnolipids and di-rhamnolipid derivatives from Lysinibacillus sp. BV152.1 and Pseudomonas
aeruginosa determined after 24 h incubation.
Rhamnolipids MICa (µg mL−1) P. aeruginosa PAO1 P. aeruginosa DM50 S. aureus ATCC 25923 S. aureus MRSA S. marcescens ATCC 27117
Lysinibacillus sp. BV152.1
di-Rha mixture (F3) >500 >500 >500 >500 >500
di-Rha-Bn >500 >500 >500 >500 >500
di-Rha-Pip >500 >500 >500 250 >500
di-Rha-Mor >500 >500 >500 >500 >500
di-rha-TBDMS >500 >500 >500 >500 >500
P. aeruginosa
R90 >500 >500 250 250 >500
di-Rha >500 >500 >500 >500 >500
di-Rha-Bn >500 >500 62.5 125 >500
di-Rha-Pip >500 >500 62.5 62.5 >500
di-Rha-Mor >500 >500 62.5 62.5 >500
di-Rha-TBDMS >500 >500 >500 >500 >500
aThe minimum inhibitory concentration (MIC) determined as the lowest concentration of compound at which no evident growth was observed. Values are the average of
two independent experiments performed in four wells.
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FIGURE 1 | Structural characterization of di-rhamnolipids (F3) isolated from Lysinibacillus sp. BV152.1. (A) 1H NMR spectrum of F3, (B) HPLC chromatogram of F3,
and (C) thin layer chromatography of Pseudomonas aeruginosa rhamnolipids (R90), purified di-rhamnolipids from R90 (di-Rha) and di-rhamnolipids fraction isolated
from Lysinibacillus sp. BV152.1 culture (F3).
FIGURE 2 | Inhibition of P. aeruginosa PAO1 biofilm formation with (A) di-rhamnolipids produced by Lysinibacillus sp. BV152.1 (F3) and (B) P. aeruginosa
(rhamnolipids mixture and purified di-Rha). ∗P < 0.05.
both sources showed an equal potency in inhibition of biofilm
formation at concentrations above 50 µg mL−1.
Di-rhamnolipids from Lysinibacillus sp. BV152.1 efficiently
inhibited bacterial adhesion to the polystyrene surface of
microtiter plates and also to the surface of silicone catheters or
glass coverslips as visualized by SEM and fluorescent microscopy,
respectively (Figure 3).
Production of rhamnolipids in P. aeruginosa enables its
swarming motility (Caiazza et al., 2005). Therefore, the effect
of di-rhamnolipids on P. aeruginosa PAO1 swarming motility
was analyzed next and the results showed that both F3 and R90
stimulated swarming in dose-dependent manner (Supplementary
Figure S1). The observed effect was more prominent in the
presence of di-rhamnolipids from Lysinibacillus sp. BV152.1.
Derivatization of Di-Rhamnolipids and
Their Antibacterial and Cytotoxic
Properties
The semi-synthetic approach of generating amide derivatives
from two different sources of di-Rha was straightforward, with
products obtained in high purity and yields from 25 to 55%
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FIGURE 3 | Inhibition of cell attachment and biofilm formation with di-rhamnolipids from Lysinibacillus sp. BV152.1. Biofilms P. aeruginosa PAO1 were formed for
24 h on silicone catheter (A,B) or glass (C,D) in the presence of DMSO (0.1%) or F3 (50 µg mL−1). Biofilms were analyzed by scanning electron microscopy (SEM;
A,B) or fluorescent microscopy (C,D). In (C,D) bacteria labeled with Syto9 appeared green and bacteria stained with propidium iodide (PI) are red, scale bars
represent 10 µm.
(Figure 4). Products were characterized using NMR and LC-MS
(Supplementary Figures S2–S5). In addition, silylated derivative
(di-Rha-TBDMS) was also generated for the control purposes.
Physico-chemical parameters for all compounds were calculated
revealing the HLB value ranging from 8.72 to 11.09 for di-Rha
and amide derivatives, while this value for di-Rha-TBDMS was
5.35 (Figure 4). It is known that compounds with HLB 7–11 are
considered wetting agents and water in oil emulsifiers, while the
ones having HLB between 4 and 6 as water in oil emulsifiers
(Pasquali et al., 2008; Muller et al., 2012). pKa was three times
higher for amide derivatives in comparison to di-Rha and di-
Rha-TBDMS indicating that they were weaker acids. logP was
between 3.36 and 5.07 for di-Rha and amide derivatives, while
this value for di-Rha-TBDMS was 3–5 times higher, suggesting
higher hydrophilicity of amide derivatives (Figure 4). Spectral
data for the new compounds are provided in Supplementary
material.
Antibacterial activity of all derivatives obtained from both
rhamnolipids sources against P. aeruginosa PAO1, P. aeruginosa
DM50, S. aureus ATCC 25923, S. aureus MRSA and S. marcescens
was addressed. Neither F3 nor di-Rha derivatives obtained
from Lysinibacillus sp. BV152.1 exhibited antibacterial activity
at concentrations up to 500 µg mL−1 against any of the
bacterial species tested (Table 1). None of the derivatives
synthetized from P. aeruginosa di-Rha affected P. aeruginosa
and S. marcescens growth. However, P. aeruginosa derivatives di-
Rha-Pip and di-Rha-Mor exhibited bactericidal activity against
S. aureus ATCC 25923 strain and S. aureus MRSA with
MIC concentrations 62.5 µg mL−1. Derivative Rha-Bn from
P. aeruginosa demonstrated the same antibacterial activity against
S. aureus MRSA.
Cytotoxicity of rhamnolipids mixture (R90), di-Rha mixture
(F3), purified di-Rha and their derivatives was analyzed
(Figure 5). Viability of human lung fibroblasts (MRC5) was not
affected in the presence of F3, di-Rha and di-Rha-TBDMS when
applied in concentrations up to 100 µg mL−1. Rhamnolipids
mixture R90 showed cytotoxic effect with IC50 value 50 µg mL−1.
Derivatization of di-Rha substantially increased their cytotoxicity
reaching almost 100% cells killing at concentrations of 25 µg
mL−1. These concentrations were 2.5-fold lower than their MIC
concentration values against S. aureus strains (Table 1) and
potentially are limiting factor in their further development as
antibiotics.
Anti-biofilm Activity of Di-Rhamnolipids
and Their Amide Derivatives
Anti-biofilm properties of di-rhamnolipids and their derivatives
were examined by addressing their influence on biofilm
formation, cell adhesion and disruption of pre-formed biofilms.
Biofilm formation in P. aeruginosa PAO1 was quantified
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FIGURE 4 | Chemical structures of di-Rha (C10-C10) and amide derivatives synthesized in this study with calculated parameters hydrophilic-lipophilic balance
(HLB), acid dissociation constant (pKa), partition coefficient (logP).
in the presence or absence of di-rhamnolipids and their
derivatives. Derivative di-Rha-Mor from Lysinibacillus sp.
BV152.1 showed increased anti-biofilm formation activity
compared to di-rhamnolipids mixture F3 (BFIC50 = 12.5 µg
mL−1) inhibiting 90% biofilm formation at 100 µg mL−1
(Figures 6A, 7). Anti-biofilm formation activity of di-Rha-
Bn and di-Rha-Pip was twofold lower than that of F3
(BFIC50 = 100 µg mL−1). Amide derivatization of di-Rha from
P. aeruginosa significantly improved activities of all derivatives
with BFIC50 = 10 µg mL−1 (Figures 6B, 7). However, maximum
activity was reached already at 50 µg mL−1 with biofilm
formation inhibition up to 60%. Derivatives di-Rha-TBDMS
from both sources, showed no anti-biofilm formation activity.
To measure anti-adhesion activity of di-rhamnolipids and
their amide derivatives, GFP fluorescence of P. aeruginosa PAO1-
GFP was used to quantify bacterial adhesion 2 h after inoculation.
Relative to the amount of adhered bacteria without treatment
(containing 0.1% DMSO), derivatives di-Rha-Bn and di-Rha-Pip
from Lysinibacillus sp. BV152.1 inhibited PAO1-GFP adhesion by
50% at concentrations 10 µg mL−1, while di-Rha-Mor showed
50% adhesion inhibition at 50 µg mL−1 (Figure 6C). Again,
derivatives from P. aeruginosa exhibited less prominent anti-
adhesive activities inhibiting P. aeruginosa PAO1-GFP adhesion
up to 35% at concentrations 100 µg mL−1 (Figure 6D).
Derivative di-Rha-TBDMS showed no significant anti-adhesion
activity. Importantly, di-Rha and their derivatives did not affect
GFP expression nor quenched its fluorescence (Supplementary
Figure S10).
Potential to disperse formed biofilm is often more relevant
to medical applications, and more challenging than inhibition
of biofilm formation. Therefore, the ability of di-rhamnolipids
and their amide derivatives to disperse 24 h old P. aeruginosa
biofilms was examined next (Figures 6E,F, 8). Di-rhamnolipids
from Lysinibacillus sp. BV152.1 (F3) were more effective in
biofilm disruption with BDIC50 10 µg mL−1 (BDIC50 is the
concentration of compound that caused 50% biofilm disruption)
comparing to di-Rha from P. aeruginosa which disrupted
biofilms up to 20% at concentrations 100 µg mL−1. The
strongest biofilm dispersion activity was measured for di-
Rha-Mor derivatives from both sources, with BDIC50 values
12.5 and 50 µg mL−1 from Lysinibacillus sp. BV152.1 and
P. aeruginosa, respectively. Both di-Rha-Mor derivatives were
able to disrupt more than 80% of pre-formed biofilms when
applied at 100 µg mL−1.
Taken together, these results demonstrated that amide
derivatization improved di-rhamnolipids anti-biofilm properties,
with di-Rha-Mor derivative being the most active compound.
The results were confirmed by comparing anti-biofilm formation
activities of di-rhamnolipids and their amide derivatives against
different bacterial species (Tables 2, 3). The improvement
of rhamnolipids anti-biofilm formation activity with amide
derivatization was more prominent with di-rhamnolipids from
Lysinibacillus sp. BV152.1. Anti-biofilm formation activity of
these derivatives was species specific with the highest activity
observed for di-Rha-Bn and di-Rha-Pip against S. aureus ATCC
25923 (>90% inhibition). All three derivatives were active
against S. marcescens biofilm formation (>80%), while the
highest activity against P. aeruginosa biofilms was observed
for di-Rha-Mor inhibiting 80% biofilm formation. The most
active P. aeruginosa di-Rha derivative was also di-Rha-Mor,
with improved anti-biofilm formation activity compared to
di-Rha against S. aureus and S. marcescens (70% and 85%
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FIGURE 5 | Cytotoxic effects of rhamnolipids mixtures, di-rhamnolipids and
their derivatives from Lysinibacillus sp. BV152.1 (A) and P. aeruginosa (B) on
human fibroblasts (MRC5) measured by MTT method, following 48 h
exposure. Values are representative of two independent experiments ± SD.
inhibition at 50 µg mL−1, respectively). The strongest inhibition
of P. aeruginosa PAO1 biofilm formation was achieved with
P. aeruginosa di-Rha-Bn and di-Rha-Pip treatments, while
none of the derivatives affected biofilm formation in clinical
isolate P. aeruginosa DM50 (Table 2). Derivatization of di-
rhamnolipids from both sources also improved their biofilm
dispersion activity against P. aeruginosa DM50, S. aureus ATCC
25923 and S. aureus MRSA (Table 3). Dispersion of S. marcescens
biofilms was efficient only with di-Rha-Bn and di-Rha-Mor from
Lysinibacillus sp. BV152.1 (63% and 58% biofilm dispersion at
50 µg mL−1, respectively). Di-Rha from both sources and the
other derivatives showed no biofilm dispersion activity against
this bacterium, most likely be due to slightly different carbon
chain length between di-rhamnolipid sources.
DISCUSSION
Rhamnolipids are amphiphilic glycolipids biosynthesized by
bacteria that, due to their low toxicity and biodegradability,
are potential replacements for synthetic surfactants. For
P. aeruginosa, secretion of rhamnolipids is critical for biofilm
formation, dispersion of bacteria from the mature biofilms and
for their swarming motility (Davey et al., 2003; Nickzad and
Deziel, 2014; Wittgens et al., 2016). Rhamnolipids are mainly
produced by species of P. aeruginosa, ubiquitous opportunistic
pathogen, which makes the isolation of novel safer natural
producers an important task. In the present study, during an
effort of identification of novel bacterial secondary metabolites
with anti-biofilm activity, a new rhamnolipid producing
bacterial strain has been isolated from the plant rhizosphere
and identified as Lysinibacillus sp. BV152.1. Members of this
Gram-positive genus, with the ability to form endospores under
harsh environmental conditions, have been isolated from various
environments, however, they are often found in soil and in
association with plants (Ouoba et al., 2015; Fredsgaard et al.,
2017; Govindasamy et al., 2017; Yan et al., 2017). L. fusiformis
S9, isolated from the river bank soil sample in India, has been
reported to produce glycolipids with surfactant properties,
but the identity of the sugar moiety was not confirmed and in
contrast to BV152.1 isolate, the unsaturated alkanoic acid was
predominant lipid chain (Pradhan et al., 2014). Therefore this
is the first report that undoubtedly confirmed the production of
rhamnolipids by a strain belonging to genus Lysinibacillus. Some
bacteria are known to produce only mono-rhamnolipids, while
some produce mono- and di-rhamnolipids in various ratios,
depending on the culture conditions. Here, anti-biofilm activity
guided fractionation and purification of the bacterial culture
extract lead toward the identification of pure di-Rha fraction
(Figure 1).
It is well documented that rhizosphere microorganisms
show wide ability to produce secondary metabolites with
the pronounced antagonistic activity toward plant pathogens
(Compant et al., 2005). Other bacterial isolates from the
plant rhizosphere producing rhamnolipids have been isolated,
however, they mostly belonged to Pseudomonas genus (Sharma
et al., 2007). Rhamnolipid production level of Pseudomonas sp.
GRP3 was comparable to production of di-Rha in Lysinibacillus
sp. BV152.1 (0.041 vs. 0.06 g L−1), however, Pseudomonas sp.
GRP3 mainly produced mono-Rha. The di-rhamnolipid fraction
of this strain had similar composition to Lysinibacillus sp.
BV152.1, with Rha-Rha-C10-C10 being the most prominent
(87%), followed by Rha-Rha-C8-C10 and Rha-Rha-C10-C12
(Sharma et al., 2007). In general, the principal rhamnolipids
considered to be produced by P. aeruginosa are Rha-C10-
C10 and Rha-Rha-C10-C10 (Maier and Soberón-Chávez, 2000;
Muller et al., 2010). Rhamnolipids can be commercially produced
by P. aeruginosa at the level of 100 g L−1, upon extensive
optimizations of fermentation conditions (Maier and Soberón-
Chávez, 2000; Muller et al., 2012; Dobler et al., 2016). The
fatty acid chain may vary from 8 to 14 carbon molecules
(Abdel-Mawgoud et al., 2010). However, it was shown that
biotechnologically obtained β-hydroxy alkanoic, of this carbon
chain range, acids have moderate antimicrobial activity, but can
be a good platform for synthesis of non-toxic molecules with
improved antimicrobial properties (Radivojevic et al., 2016).
Biosurfactants, including rhamnolipids, affect the initial
attachment on various surfaces, thus help prevention of the
biofilm formation (Neu, 1996; Vatsa et al., 2010; Sodagari
et al., 2013; Zhong et al., 2015). It was demonstrated that
rhamnolipids (mixture of Rha-C10-C10 and di-Rha-C10-C10)
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FIGURE 6 | Pseudomonas aeruginosa PAO1 biofilm formation (A,B), cell adhesion (C,D), or biofilm disruption (E,F; %) in the presence of di-rhamnolipids isolated
from Lysinibacillus sp. BV152.1 (A,C,E) or P. aeruginosa (B,D,F) and their derivatives. Values are presented as mean ± SD. ∗P < 0.05.
could prevent the attachment of P. aeruginosa, P. putida, and
Escherichia coli, as well as S. epidermidis and Bacillus subtilis
on glass and octadecyltrichlorosilane modified hydrophobic glass
in concentration range from 10 to 200 µg mL−1 to various
extent (Sodagari et al., 2013). Inhibition of microbial growth, as
well as a change of cell surface hydrophobicity was examined
as a potential mechanism for this activity, but the responsible
mechanism of the observed effect remained unknown. In the
case of di-Rha utilized in this study, the antimicrobial effect has
not been observed for concentrations up to 500 µg mL−1, while
from the comparison of anti-biofilm activity with and without
cell adhesion phase, it can be concluded that at concentrations
of 50 µg mL−1 and above di-Rha reduced cell adhesion, while
at lower concentrations affected biofilm maturation. Similarly,
glycolipids from L. fusiformis S9 were found to inhibit bacterial
attachment and caused the complete inhibition of E. coli and
Streptococcus mutans biofilm formation at 40 µg mL−1 without
affecting their growth (Pradhan et al., 2014). Di-Rha from
both sources efficiently inhibited biofilm formation on different
microorganisms including two antibiotic-resistant S. aureus
MRSA and clinical isolate P. aeruginosa DM50 strains and were
efficient on two types of surfaces, silicone catheter and glass.
Both of these findings have great value for the possible future
applications in biomedicine.
Previously limited access to relatively pure rhamnolipid
materials at the gram scale has hindered extensive
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FIGURE 7 | Pseudomonas aeruginosa PAO1 biofilm formation on plastic surfaces in the presence of 0.1% DMSO (A), F3 (B), di-Rha-Mor derivative from
Lysinibacillus sp. BV152.1 (C), or di-Rha (D), and di-Rha-Mor derivative from P. aeruginosa (E) at 50 µg mL−1. Biofilms were stained with Syto9 (green) and PI (red),
scale bars represent 10 µm.
characterization of rhamnolipid structure-activity relation.
Here, an efficient semi-synthetic methodology has been applied
to the mixture and pure di-Rha, yielding three amide derivatives
that were prepared and subsequently characterized for the first
time. Chemical derivatization of the natural products is not a
new concept, but has not been previously applied on di-Rha
substrates. Indeed, based on our results, it should be further
explored as a platform for obtaining new diverse rhamnolipids
with improved properties. It is worth mentioning that similar
semi-synthetic approach was previously applied using natural
sophorolipid mixture (another class of biological glycolipids) as
a substrate in reaction with the sodium alkoxides to form the
corresponding sophorolipid alkyl (methyl, ethyl, propyl, and
butyl) esters derivatives (Zhang et al., 2004).
A series of 14 synthetic rhamnolipids, inspired by the natural
Rha-C14-C14, naturally produced by Burkholderia plantarii,
has been achieved using hydrophobically assisted switching
phase synthesis and their physico-chemical properties, as well
as bioactivity in terms of cytokine induction, were examined
(Howe et al., 2006). Derivatives differed in acylation pattern,
number of monosaccharide residues, and the charge resulting in
a large variety of activities, from the complete lost to antagonistic
activity. Indeed, generating three aromatic amide derivatives
from two different sources of di-Rha, we have observed a
general increase in antimicrobial, anti-biofilm formation, as well
as biofilm disruption and antiproliferative activities. Carboxylic
group of the bioactive compounds is often modified into
various amide derivatives in order to mask free carboxylic
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FIGURE 8 | Dispersion of P. aeruginosa PAO1 biofilms pre-formed on plastic surfaces (A) with 50 µg mL−1 F3 (B), di-Rha-Mor derivative from Lysinibacillus sp.
BV152.1 (C), di-Rha (D), or di-Rha-Mor derivative from P. aeruginosa (E). Biofilms were stained with Syto9 (green) and PI (red), scale bars represent 10 µm.
group, commonly cause an increase in lipophilicity and tailor
their biological activity (Chhikara et al., 2011; Guan et al.,
2014). This was especially true for the di-Rha-Mor, that was
determined to be the most potent derivative, and the only one that
showed the antibacterial effect against both strains of S. aureus
with MIC concentration values of 62.5 µg mL−1 (Table 1).
Similarly, the introduction of morpholine moiety resulted in
the increase of activity of 4-oxo-4H-pyrido[1,2-a]pyrimidine
in its ability to potentiate the activity of Levofloxacin and
Aztreonam against P. aeruginosa (Yoshida et al., 2006). Generally,
morpholine derivatives are gaining considerable importance
due to diverse biological activities including antibacterial and
antiproliferative (Jakubowska et al., 2008; Hirokawa et al.,
2009; Seelolla et al., 2014). Relatively small differences in the
structure of the three amide derivatives generated in this
study caused different biological effect. On the other side, the
difference in the activities between rhamnolipid compounds
from two sources was small and could be attributed to
the fact that derivatives from the Lysinibacillus sp. BV152.1
contained the mixture of congeners of various carbon chain
fatty acids, while the one from P. aeruginosa was pure C10-C10.
Interestingly, derivative di-Rha-TBDS bearing bulky protective
groups on the rhamnoses lost all the biological activities,
suggesting that sugar moieties play a crucial role in the
activity of these molecules. Indeed, this derivative had the
lowest HLB and the highest logP amongst studied molecules
suggesting the loss of amphiphilic nature of rhamnolipid
molecules.
Rhamnolipids are usually considered as non-toxic, however,
several reports confirmed that in concentrations of 100 and
Frontiers in Microbiology | www.frontiersin.org 12 December 2017 | Volume 8 | Article 2454
fmicb-08-02454 December 6, 2017 Time: 16:21 # 13
Aleksic et al. Di-Rhamnolipid Derivatives Efficient Anti-biofilm Agents
TABLE 2 | Biofilm formation (%) in the presence of rhamnolipids mixture (R90), di-rhamnolipids, and di-rhamnolipid derivatives from Lysinibacillus sp. BV152.1 and
P. aeruginosa.
Rhamnolipids 50 µg mL−1 P. aeruginosa PAO1 P. aeruginosa DM50 S. aureus ATCC 25923 S. aureus MRSA S. marcescens ATCC 27117
Lysinibacillus sp. BV152.1
di-Rha mixture (F3) 50 ± 5 45 ± 3 78 ± 12 80 ± 3 38 ± 13
Rha-Bn 60 ± 2 42 ± 2 4 ± 0.5 66 ± 7 20 ± 4
Rha-Pip 50 ± 2 48 ± 4 4 ± 0.5 67 ± 5 20 ± 4
Rha-Mor 20 ± 3 35 ± 8 11 ± 2 28 ± 2 12 ± 1
Rha-TBDMS 115 ± 10 100 ± 8 88 ± 12 106 ± 4 85 ± 1
P. aeruginosa
R90 54 ± 5 76 ± 8 43 ± 6 42 ± 3 15 ± 2
di-Rha 50 ± 3 109 ± 10 37 ± 4 44 ± 11 20 ± 5
di-Rha-Bn 36 ± 3 168 ± 3 39 ± 2 48 ± 10 50 ± 7
di-Rha-Pip 39 ± 4 94 ± 13 31 ± 2 34 ± 3 20 ± 3
di-Rha-Mor 50 ± 4 76 ± 7 27 ± 2 30 ± 3 14 ± 1
di-Rha-TBDMS 95 ± 7 73 ± 6 88 ± 10 69 ± 11 117 ± 4
Values are presented as mean ± SD.
TABLE 3 | Biofilm biomass (%) remained after biofilm dispersion with di-rhamnolipids and di-rhamnolipid derivatives from Lysinibacillus sp. BV152.1 and P. aeruginosa.
Rhamnolipids 50 µg mL−1 P. aeruginosa PAO1 P. aeruginosa DM50 S. aureus ATCC 25923 S. aureus MRSA S. marcescens ATCC 27117
Lysinibacillus sp. BV152.1
di-Rha mixture (F3) 53 ± 5 108 ± 7 115 ± 13 88 ± 7 243 ± 3
Rha-Bn 46 ± 2 74 ± 4 64 ± 5 62 ± 11 37 ± 2
Rha-Pip 52 ± 5 67 ± 4 87 ± 5 86 ± 10 180 ± 7
Rha-Mor 32 ± 2 75 ± 8 68 ± 10 63 ± 12 42 ± 4
Rha-TBDMS 80 ± 6 65 ± 1 110 ± 22 101 ± 14 99 ± 8
P. aeruginosa
di-Rha 77 ± 3 135 ± 10 80 ± 9 82 ± 7 193 ± 8
di-Rha-Bn 84 ± 8 70 ± 6 62 ± 5 55 ± 10 239 ± 15
di-Rha-Pip 63 ± 4 59 ± 5 80 ± 7 54 ± 2 175 ± 18
di-Rha-Mor 44 ± 6 67 ± 8 44 ± 4 70 ± 6 160 ± 8
di-Rha-TBDMS 76 ± 10 78 ± 10 82 ± 3 120 ± 10 155 ± 3
Values are presented as mean ± SD.
150 µg mL−1 they reveal significant toxicity and their antitumor
activity has been focused on (Christova et al., 2013; Jiang
et al., 2014). Rhamnolipids were reported to show considerable
cytotoxicity on HeLa cells at a low concentration of 5 mg
L−1 (Lotfabad et al., 2010). However, we found that di-
Rha were not toxic to normal human fibroblasts up to
100 µg mL−1, while the antiproliferative properties increased
when cells were treated with amide derivatives. This is in
line with the recent study confirming that rhamnolipids, like
chemical surfactants, exhibited cytotoxicity by reducing the
surface tension of culture medium rather than by changing
its specific molecular structure, which had no selection on
tumor cells and that natural rhamnolipids are not promising
antitumor agents (Jiang et al., 2014), however, simple chemical
alterations may increase their cytotoxicity. We also confirm
findings that natural rhamnolipids have no direct antibacterial
activity in concentrations of up to 500 µg mL−1 against
P. aeruginosa, S. aureus, and S. marcescens, while others
have reported MIC values in a range 4–32 mg L−1 against
bacteria Enterobacter aerogenes, Proteus mirabilis, P. aeruginosa,
Salmonella Typhimurium, S. aureus, B. cereus, B. subtilis,
Streptococcus faecalis and numerous fungal strains (Benincasa
et al., 2004; Vatsa et al., 2010). Nevertheless, the most
prominent activity of rhamnolipids is within their anti-
biofilm properties that have been confirmed in numerous
studies, involving wide range of rhamnolipid producers and
pathogenic biofilm forming strains (Irie et al., 2005; Dusane
et al., 2011, 2012; De Rienzo and Martin, 2016; Díaz De
Rienzo et al., 2016). Similar to activities observed in this
work, purified di-rhamnolipids from P. aeruginosa ATCC 9027
completely disrupted P. aeruginosa PAO1 pre-formed biofilms
at concentrations 150 µg mL−1 (Davey et al., 2003). Less
efficient were P. aeruginosa rhamnolipids against B. pumilus
biofilms with BDIC50 = 580 µg mL−1 and complete biofilm
inhibition at 50 mg mL−1 (Dusane et al., 2010). Generally
lower in comparison to activities reported in this study but
still potent biofilm disruption activities against important oral
pathogens [S. oralis (BDIC70 = 750 µg mL−1), Actinomyces
naeslundii, Neisseria mucosa, and S. sanguinis (BDIC90 = 190 µg
mL−1)] and biofouling strains S. capitis and B. licheniformis
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(BDIC50 = 40 µg mL−1) were reported for rhamnolipids
mixture purified from B. thailandensis containing mainly long
chain Rha-Rha-C14-C14 di-rhamnolipids (Chebbi et al., 2017;
Elshikh et al., 2017). Biofilm-related infections have been
encountered in chronic diseases such as cystic fibrosis, otitis
media, ventilator-associated pneumonia, and periodontitis, or in
chronic wounds that have an impaired blood supply. Biofilms are
often implicated in low sensitivity or resistance to antimicrobials.
Thus, considering their broad-spectrum activity against bacteria
and low cytotoxicity to human cells, di-Rha could be used
to improve the effectiveness of antibiotics through biofilm
inhibition, particularly for the treatment of chronic wound
infections or in prophylactics of periodontal diseases. Besides,
biofilms can be formed on the surface of medical devices (Bryers,
2008). Di-Rha and their derivatives could be used to functionalize
the materials for medical usage in order to inhibit bacterial
adhesion and formation of the biofilms on their surfaces, thus
minimizing the spreading of the bacteria to the patients.
Recently, a series of synthetic rhamnolipid analogs including
disaccharide maltose or cellobiose tethered with different
aliphatic chains were prepared and their effect on the biofilm
formation in P. aeruginosa rhamnolipid non-producing strain
has been assessed (Zheng et al., 2017). As in our study, it has
been shown that small structural details of these molecules are
important for the bioactivities. Synthetic structural analogs of
rhamnolipids promoted biofilm formation by non-rhamnolipid
producing mutant at low concentrations but inhibited the biofilm
formation at high concentrations such as 170 and 220 µg mL−1
(Zheng et al., 2017). Promotion of biofilm formation has not been
observed during our study, while efficient inhibition of biofilm
formation was observed at 10 and 50 µg mL−1.
CONCLUSION
Anti-biofilm activity guided screening of culture extracts lead
to the identification of rhizosphere isolate Lysinibacillus sp.
BV152.1 producing a mixture of di-rhamnolipids. The di-
rhamnolipid fraction was found to be a potent anti-biofilm
agent for the pathogenic P. aeruginosa PAO1 and DM50,
S. aureus (ATCC 25923 and MRSA) and S. marcescens
ATCC 27117 strains, while having no effect on the bacterial
growth and showing low in vitro cytotoxicity against human
fibroblasts. Isolated di-Rha from Lysinibacillus sp. BV152.1 and
from the commercially available rhamnolipid mixture from
P. aeruginosa were used as substrates for generation of semi-
synthetic amide derivatives, for the first time. Introducing amide
functional group resulted in a general increase of biological
activities. Thus, the semi-synthetic approach could be further
explored for obtaining diverse rhamnolipids with improved
activities.
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